Trial Profile
A study investigating the effect of natalizumab on miR-126 and POU2AF1 expression in CD4+ T cells in relapsing remitting multiple sclerosis patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Dec 2015
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 08 Dec 2015 New trial record